TRKA Stock
TRKA Stock

It has been discussed a lot lately about which are the best cannabis stocks. In the United States, recreational marijuana is legal in several states, and medical marijuana is legal in most. Investors have to find out which cannabis stocks present the best opportunities.

What are the benefits of cannabis stocks?

Currently, the United States is the largest market for cannabis in the world, with the cannabis industry set to thrive globally. The value of the best cannabis stocks is expected to reach $30 billion by 2025, according to Investopedia. Meanwhile, Cannabiz Media predicts that the US cannabis industry will hit the figure of $160.7 billion by 2025. Regardless of the statistics, the cannabis market is mushrooming.

How can you use this information to your advantage?

There are numerous ways to generate revenue in the cannabis industry because of the wide variety of revenue-generating opportunities. Below are the three best cannabis stocks you may want to consider before the year ends.

AbbVie Inc. (ABBV) saw a downtrend of -0.96% in the recent trading with $116.06 being its most recent. The current price level is 4.5% lower than the highest price of $121.53 marked by the stock while trading over the past 52-weeks, whereas it is -26.55% higher than the lowest price of $91.71 the company dropped to over the past 52-weeks.

According to WSJ, AbbVie Inc. (NYSE: ABBV) obtained an estimated Overweight proposal from the 22 brokerage firms currently keeping a deep eye on the stock performance as compares to its rivals. 0 equity research analysts rated the shares with a selling strategy, 5 gave a hold approach, 13 gave a purchase tip, 4 gave the firm overweight advice, and 0 put the stock under the underweight category. The average price goal of one year between several banks and credit unions that last year discussed the stock is $129.26.

The stock of Anheuser-Busch InBev SA/NV (BUD) decreased by -0.81% to finish the standard trading session at $60.29. During that period, a total of 0.96 million shares were traded, and this stock’s average trading volume is currently 2.25M shares per day. Important things to pay attention to when considering a stock’s current and future price are the 52-week high and low price points. Shares of Anheuser-Busch InBev SA/NV (BUD) are currently -24.33% below their 52-week high mark and 11.49% higher than the 52-week low mark.

Out of a total of 32 brokerages that are currently covering Anheuser-Busch InBev SA/NV (BUD) stock, the average recommendation is “Overweight” according to WSJ. 1 equities research analyst has rated the stock with an “Overweight” recommendation, 18 analysts have given this stock a “Buy” recommendation, 11 analysts have recommended that investors “Hold” this stock, and 2 analysts have given this stock a “Sell” rating and 0 suggested “Underweight”. Analysts’ average 1-year price target, among all the brokerages, is $71.50.

In the most recent purchasing and selling session, Altria Group Inc. (MO)’s share price decreased by -0.29 percent to ratify at $45.07. A sum of 5.86 million shares traded at the recent session and its average exchanging volume remained at 6.90M shares. The 52-week price high and low points are important variables to concentrate on when assessing the current and prospective worth of stock. Altria Group Inc. (MO) shares are taking a pay cut of -14.30% from the high point of 52 weeks and flying high of 21.58% from the low figure of 52 weeks.

Investors are for sure keenly observing the recommendations of analysts at Wall Street about the Altria Group Inc. And review of current evaluations agreed by the analysts discloses an Overweight rating for mo. The simple numeric range of brokerage firms referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock. Lower value of between 0 and 2 implies a Buy recommendation whereas the value in the range of 2 to 3 suggests Hold while above 3 recommends the investors to sell the stock. Currently, the stock has been recommended as an Overweight by 19 of the Wall Street analysts.


Please enter your comment!
Please enter your name here